TUESDAY, Aug. 10 (HealthDay News) -- People who take oral bisphosphonate drugs to prevent or treat osteoporosis are not at a significantly increased risk for esophageal or stomach cancer, according to an analysis of more than 80,000 patients in the United Kingdom.
